DAY 1: 6/23/25 Segmented Liver Tumor Research Meeting Agenda
Date
Time
Topic
Speaker
6/23/25
7-7:45 am
Registration/Breakfast
7:45-8:05 am
Alejandro Sweet-Cordero
7:45-7:55 am
Arun Rangaswami
7:55-8:05 am
Welcome
Alejandro Sweet-Cordero, MD
UCSF Benioff Children’s Hospitals
Arun Rangaswami, MD
UCSF Benioff Children’s Hospitals
8:05-8:25 am
Jim Feusner
8:05-8:25 am
Keynote
James Feusner, MD
UCSF Benioff Children’s Hospitals
8:25- 9:55 am
Greg Tiao
8:25- 8:40 am
Eiso Hiyama
8:40- 8:55 am
Madhu Dandapani
8:55-9:10 am
Jozsef Zsiros
9:10-9:25 am
Angela Trobaugh-Lotrario
9:25- 9:40 am
Kate Somers
9:40-9:55 am
Trial/Pilot Study Status
Paediatric Hepatic International Tumour Trial (PHITT)
Greg Tiao
Pediatric Hepatic International Tumour Trial (PHITT)/JPLT4: Current Status in JCCG
Eiso Hiyama
A Global Effort, A European Perspective: Insights from the PHITT trial
Madhumita Dandapani
European High Risk EXPLORER Pilot (SIOPEL)
Jozsef Zsiros
High Risk Hepatoblastoma Pilot
Angela Trobaugh-Lotrario
Cisplatin/STS/SAHA for relapsed HB
Kate Somers
Alli O’Neill, MD
Dana-Farber Cancer Institute
Tomoro Hishiki, MD, PhD
Chiba University Hospital
Sophie Branchereau, MD
Bicêtre Hospital – University of Paris-Saclay
Kate Somers, MD
Cincinnati Children’s Hospital
Greg Tiao, MD
Cincinnati Children's Hospital
Eiso Hiyama, MD, PhD
Hiroshima University
Madhumita Dandapani, MBBS, MRCPCH, PhD
University of Nottingham
Jozsef Zsiros, MD
Princess Máxima Center
Angela Trobaugh-Lotrario, MD
Sacred Heart Medical Center – Providence
9:55- 10:05 am
Coffee Break
10:05-11:30 am
Eiso Hiyama
10:05-10:20 am
Lola López-Terrada
10:20- 10:45 am
Carolina Armengol Niell
10:45-11 am
Peng Wu
11- 11:15 am
Weng Chuan Peng
11:15- 11:30 am
Hepatocellular Neoplasms Biology & Pathology
DNA Methylation Status for Prognosis Prediction in Hepatoblastoma
Eiso Hiyama
Biomarker Consensus Analysis
Lola Lopez-Terrada
Precision Medicine for HB
Carolina Armengol Niell
Rewired Developmental Growth Signals in Hepatoblastoma
Peng Wu
Omics and Organoids: Decoding Tumor Heterogeneity and Identifying Therapeutic Targets for Hepatoblastoma
Weng Chuan Peng
Lola López-Terrada, MD, PhD
Texas Children's Hospital
Eiso Hiyama, MD, PhD
Hiroshima University
Carolina Armengol Niell, PhD
Germans Trias i Pujol Research Institute
Peng Wu, MD, PhD
Cincinnati Children’s Hospital
Weng Chuan Peng, PhD
Princess Máxima Center
11:30-12:05 pm
Amar Nijagal
11:30-11:45 am
Rob Schwartz
11:45-12 pm
Bruce Wang
12-12:15 pm
Development Biology/Pathophysiology: Status and Future
Defining the Immunoregulatory Environment of the Developing Liver: A Friend or Foe for Hepatoblastoma
Amar Nijagal
Modeling Human Hepatoblastoma Using Bioengineered Tissues
Rob Schwartz
Hepatoblastoma Tumor Heterogeneity at a Single-Cell Level
Bruce Wang
Lola López-Terrada, MD, PhD
Texas Children's Hospital
Amar Nijagal, MD
UCSF Benioff Children’s Hospitals
Rob Schwartz, MD, PhD
New York-Presbyterian Hospital Weill Cornell Medical Center
Bruce Wang, MD
UCSF Benioff Children’s Hospitals
12:15-1:15 pm
Lunch
Poster Viewing
1:15-2:20 pm
Roland Kappler
1:15-1:30 pm
Genta Nagae
1:30-1:45 pm
Pavel Sumazin
1:45-2:05pm
Sarah Woodfield
2:05-2:20 pm
Theo Hirsch
2:20-2:40 pm
Biology, Epidemiology, Pathology:
Biology (HB/HCN NOS)
Mechanistic Models for Predicting Drug Efficacy in Pediatric Liver Tumors
Roland Kappler
Whole Genome, Transcriptome and Methylome Analysis of 200 Pediatric Liver Cancers
Genta Nagae
Asynchronous Transitions from Hepatoblastoma to Carcinoma
Pavel Sumazin
Targeting High-Risk Features of Hepatoblastoma
Sarah Woodfield
Multiscale Analysis of Hepatoblastoma Evolution and Resistance to Cisplatin
Theo Hirsch
Pavel Sumazin, PhD
Texas Children’s Hospital
Genta Nagae, PhD
University of Tokyo
Roland Kappler, PhD
Ludwig-Maximilians-Universität in Munich
Sarah Woodfield, PhD
Baylor College of Medicine
Theo Hirsch, PhD
Cordeliers Research Center
2:40-3 pm
Genta Nagae 2:40-3 pm
Biology (HCC)
Comparative Genomics Study of Pediatric HCC in the JPLT cohort
Genta Nagae
Genta Nagae, PhD
University of Tokyo
3-4:20 pm
Soo-Jin Cho
3- 3:20 pm
Hiroko Fukushima
3:20-3:40 pm
Juan Putra
3:40-4 pm
Sarangarajan Ranganathan
4- 4:20 pm
Pathology
Histopathology of Hepatocellular Neoplasms in Patients with Select Genetic Syndromes
Soo-Jin Cho
Pathological Review of Hepatocellular Neoplasm NOS (HCN-NOS) from
Japanese Study Group for Pediatric Liver Tumor (JPLT)
Hiroko Fukushima
Pediatric Hepatocellular Adenomas: When Is Molecular Testing Useful?
Juan Putra
Malignant Hepatocellular Neoplasm: What's in a Name?
Sarangarajan Ranganathan
Soo-Jin Cho, MD, PhD
UCSF Benioff Children’s Hospitals
Sarangarajan Ranganathan, MD
Cincinnati Children’s Hospital
Hiroko Fukushima, MD, PhD
Osaka City Juso Hospital (Japan)
Juan Putra, MD
Boston Children’s Hospital
4:20-5:10 pm
Logan Spector
4:20-4:45 pm
Erin Marcotte
4:45-5:10 pm
Epidemiology
Germline Genetic Risk for Hepatoblastoma
Logan Spector
Outcomes and Survivorship in Hepatoblastoma
Erin Marcotte
Logan Spector, PhD
University of Minnesota
Erin Marcotte, PhD
University of Minnesota
5:10-5:25 pm
Coffee Break
5:25-6:20 pm
Genta Nagae
5:25-5:50 pm
Kenichirou Watanabe
5:50-6:20
HCC Mechanisms of Resistance/ Treatment
Exploration of Epigenetic Mechanism of Drug Resistance in Liver Cancer Cells
Genta Nagae
Use of Multikinase Inhibitors for Pediatric Liver Tumors
Kenichiro Watanabe
Eiso Hiyama, MD, PhD
Hiroshima University
Genta Nagae, PhD
University of Tokyo
Kenichiro Watanabe, MD, PhD
Shizuoka Children’s Hospital
6:20-6:30 pm
Day 1 Closing Remarks
Arun Rangaswami, MD
UCSF Benioff Children's Hospitals
6:30 pm
Welcome Reception
7 pm
Dinner
DAY 2: 6/24/25 Segmented Liver Tumor Research Meeting Agenda
Date
Segment Total
Speaker Segment
*ALL SEGMENTS INCLUDE 5-MIN FOR Q&A
Topic
Speaker
6/24/25
7:15-8 am
Registration/Breakfast
8-9:45 am
Gary Schooler
8-8:15 am
Eiso Hiyama
8:15-8:30 am
Genta Nagae
8:30-8:45 am
Carolina Armengol Niell
8:45-9 am
Nensi Ruzgar
9-9:15 am
Daniel Münter
9:15-9:30 am
Talita Ferreira Marques Aguiar
9:30- 9:45 am
Liver “Omics” – Biology
Radiomics
Gary Schooler
ctDNA: Advances in Diagnostic Methods and Disease Monitoring
Eiso Hiyama
Haplotype-Aware Methylation Analysis of Hepatoblastoma Genome Using Long Read Sequencing
Genta Nagae
Proteomics of Childhood Liver Cancer
Carolina Armengol Niell
Profiling Circulating Tumor DNA in Hepatoblastoma
Nensi Ruzgar
Multiomic Analysis Uncovers Wnt-MDK-Driven Immune Evasion in Hepatoblastoma
Daniel Münter
First Transcriptome Analysis of Hepatoblastoma in Brazil: Unraveling the Pivotal Role of Noncoding RNAs and Metabolic Pathways
Talita Ferreira Marques Aguir
Genta Nagae, PhD
University of Tokyo
Gary R. Schooler, MD
Cincinnati Children’s Hospital
Eiso Hiyama, MD, PhD
Hiroshima University
Talita Ferreira Marques Aguiar, PhD
Columbia University
Daniel Münter
University Children's Hospital Münster
Carolina Armengol Niell, PhD
Germans Trias i Pujol Research Institute (Spain)
Nensi Ruzgar, MD
Dana-Farber Cancer Institute
9:45-10:20 am
Alex Bondoc
9:45-9:55 am
Sophie Branchereau
9:55-10:05 am
Tomoro Hishiki
10:05-10:20 am
ICG
Alex Bondoc
Sophie Branchereau
Tomoro Hishiki
Sanjeev Vasudevan
Texas Children’s Hospital
Sophie Branchereau, MD
Bicêtre Hospital – University of Paris-Saclay
Tomoro Hishiki, MD, PhD
Chiba University Hospital
Alexander Bondoc, MD
Cincinnati Children’s Hospital
10:20-1 pm
Sanjeev Vasudevan
10:20-10:40 am
Sang-Mo
10:40-11 am
Jörg Fuchs
11-11:20 am
Sophie Branchereau
11:20-11:40 am
Eiso Hiyama
11:40-12 pm
Steven Warmann
12-12:20 pm
Ryan Lokken
12:20-12:40 pm
Anne Gill
12:40-1 pm
Advances in Local Control (Surgical/IR)
Extreme Resection vs. Transplant-Expert Opinion from a Post Hoc AHEP0731 Review
Sanjeev Vasudevan
Extreme Rsection vs. Transplant, Considerations from the Transplant Surgeon
Sang-Mo Kang
Extreme Resection of Pediatric Liver Tumors – Challenges and Future Directions Based on Selected German Cases
Jörg Fuchs
Collaboration and Potential for PHITT 2, Backup Transplant: How Much Remnant Is Too Little?
Sophie Branchereau
3D Simulation Modeling for Appropriate and Safe Resection of Pediatric Malignant Liver Tumors
Eiso Hiyama
3-Dimensional Reconstruction and Virtual Resection Planning in Advanced Hepatoblastoma
Steven Warmann
Adult approaches in locoregional management of liver tumors
Ryan Lokken
Applying Adult IR Techniques and Approaches to Pediatric Liver Tumors
Anne Gill
Sanjeev Vasudevan
Texas Children’s Hospital
Greg Tiao, MD
Cincinnati Children’s Hospital
Sophie Branchereau, MD
Bicêtre Hospital – University of Paris-Saclay
Sang-Mo Kang, MD
UCSF Benioff Children’s Hospitals
Eiso Hiyama, MD, PhD
Hiroshima University
Ryan Lokken, MD
UCSF Benioff Children’s Hospitals
Anne Gill, MD
Children’s Healthcare of Atlanta
Alexander Bondoc, MD
Cincinnati Children’s Hospital
Jörg Fuchs, MD
University of Tübingen
Steven Warmann, MD
Charité Universitätsmedizin Berlin
1-2 pm
Lunch
2-3 pm
Sandy Simon
2-2:15 pm
Marina Baretti
2:15-2:30 pm
Mike Ortiz
2:30-2:45 pm
John Gordan
2:45-3pm
FLC (JHU Vaccine Trial, FLC Pilot)
Pipelines for Developing Therapeutics for Rare Cancers: Lessons from Fibrolamellar Carcinoma
Sandy Simon
Breaking Barriers in Fibrolamellar Hepatocellular Carcinoma (FLC): Immunotherapeutic Strategies for a Rare Cancer
Marina Baretti
FLC Pilot
Mike Ortiz
Linking Health Informatics and Advocacy Build the Clinical Knowledge Base in Fibrolamellar Carcinoma
John Gordan
Sandy Simon, PhD
The Rockefeller University
Michael Ortiz, MD
Memorial Sloan Kettering Cancer Center
John Gordan, MD, PhD
UCSF Benioff Children’s Hospitals
Marina Baretti, MD
Johns Hopkins Medicine
3-4 pm
Aaron Weiss
3-3:15 pm
Zachary Kastenberg
3:15-3:30 pm
Hiroko Fukushima
3:30-3:45 pm
Jess Gartrell
3:45-4 pm
UESL
Embryonal Sarcoma of the Liver in Pediatric and Young Adult Patients Treated on COG trial ARST0332
Aaron Weiss
Undifferentiated Embryonal Sarcoma of the Liver – Surgical Decision-Making
Zachary Kastenberg
Pathological review of Embryonal sarcoma from Japanese Study Group for
Pediatric Liver Tumor (JPLT)
Hiroko Fukushima
The Inclusion of UESL in Sarcoma Trials: NRSTS2021
Jessica Gartrell
Aaron Weiss, DO
Maine Health
Zachary Kastenberg, MD, MS, FACS, FAAP
University of Utah
Hiroko Fukushima, MD, PhD
Osaka City Juso Hospital (Japan)
Jessica Gartrell, MD
St. Jude Children’s Research Hospital
4-6 pm
Greg Tiao
4-4:15 pm
Yohei Yamada
4:15-4:35 pm
Sue Rhee
4:35-4:55 pm
Emily Perito
4:55-5:15 pm
Greg Tiao
5:15-5:35 pm
Christoph Slavetinsky
5:35-6 pm
Immunosuppression/Transplant
Multivisceral OLTx for HB
Greg Tiao
The Role of Liver Transplantation in Hepatoblastoma: Outcomes from the JPLT Study and Current Practice in Japan
Yohei Yamada
Living Related Donor Transplants
Sue Rhee
Optimizing Immunosuppression After Liver Transplant for Pediatric Liver Tumors
Emily Perito
Should Salvage Transplant Be Offered for All Unresectable Relapse Confined to Liver?
Greg Tiao
Identical Living-Donor Liver and Hematopoietic Stem Cell Transplantation to Avoid Long-Term Immunosuppression in Advanced Pediatric Liver Tumors
Christoph Slavetinsky
Emily Perito, MD
UCSF Benioff Children’s Hospitals
Greg Tiao, MD
Cincinnati Children’s Hospital
Piotr Czauderna, MD, PhD
Medical University of Gdansk, Poland
Yohei Yamada, MD
Keio University (Japan)
Sue Rhee, MD
UCSF Benioff Children’s Hospitals
Christoph Slavetinsky, MD
University of Tübingen
DAY 3: 6/25/25 Segmented Liver Tumor Research Meeting Agenda
Date
Segment Total
Speaker Segment
*ALL SEGMENTS INCLUDE 5-MIN FOR Q&A
Topic
Speaker
6/25/25
7-8:30 am
Registration/Breakfast
8:30-12 pm
Patient/Family Forum
The Hepatoblastoma Resource Network
8:30-9:15 am
Welcome Introductions
Hepatoblastoma Resource Network (HRN) Parents
Dr. Arun Rangaswami
Arun Rangaswami, MD
UCSF Benioff Children’s Hospitals
9:15-9:30 am
HRN Presentation
Christina Stiverson
9:30-10 am
Natalie Wu
9:30- 9:45am
Erin Marcotte
9:45- 10 am
Late Effects
Natalie Wu
Late effects and the need for tailored survivorship guidelines
Erin Marcotte
Natalie Wu, MD
UCSF Benioff Children's Hospital
Erin Marcotte, MD
University of Minnesota
10-10:30 am
Kristin Knight
10-10:30 am
Audiology – Side Effects
Kristin Knight, MS Doernbecher Children's Hospital
10:30-10:45 am
Break
10:45-11:15 am
Irene Schmid
10:45-11 am
Kate Cheng, Arun Rangaswami
11:00-11:15 am
Provider Panel
Global Consensus from the PHITT Consortium Surrounding an Interim Chemotherapy Guidance
Irene Schmid
Q&A
Interim Guidelines
Irene Schmid, MDDr. von Hauner Children's Hospital
Kate Cheng, MD
UCSF Benioff Children’s Hospital
Arun Rangaswami, MD
UCSF Benioff Children’s Hospital
11:15- 12:00 pm
Survivor Panel- Transition of Care, Mental Health & Schooling
Survivor Panelists
12-1:30 pm
Lunch
Breakout Sessions
1:30-2:45 pm
Lena Winestone
1:30-1:50 pm
Sharad Wadhwani
1:50-2:10 pm
Arun Rangaswami
2:10-2:25 pm
Alli O’Neill
2:25-2:45 pm
Disparities
Disparities and Health Equity in Pediatric Oncology
Lena Winestone
Addressing Social Adversity to Improve Outcomes for Children After Liver Transplant
Sharad Wadhwani
UCSF Pediatric Multidisciplinary International Hepatobiliary Tumor Board
Arun Rangaswami
ARIA: A Resource-Focused Guide to the Global Care of Hepatoblastoma
Alli O'Neill
Lena Winestone, MD, MS
UCSF Benioff Children’s Hospitals
Sharad Wadhwani, MD, MPH
UCSF Benioff Children’s Hospitals
Arun Rangaswami, MD
UCSF Benioff Children’s Hospitals
Alli O’Neill, MD
Dana-Farber Cancer Institute
2:30-3:15 pm
Beate Häberle 2:30-2:45 pm
Arun Rangaswami 2:45-3:00 pm
Brice Fresneau
& Alli O'Neill
3-3:15
CHIC/PCDC, Update on projects, PCDC Migration
Validation of the CHIC Stratification System
Beate Häberle
CHIC Updates
Arun Rangaswami
AFP Decline Project
Brice Fresneau
Alli O'Neill
Eiso Hiyama, MD, PhD
Hiroshima University
Arun Rangaswami, MD
UCSF Benioff Children’s Hospitals
Beate Häberle, MD
Ludwig-Maximilians-Universität
Brice Fresneau, MD, PhD
Institut Gustave Roussy, Villejuif
Alli O'Neill, MD
Dana-Farber Cancer Institute
3:15-4:40 pm
Angela Trobaugh-Lotrario
3:15- 3:30 pm
Eiso Hiyama
3:30-3:45 pm
Alex Bondoc
3:45-4 pm
Irene Schmid
4-4:15 pm
Jim Geller
4:15-4:35 pm
Alli O’Neill
4:35-4:50
Relapse/Registries & RELIVE
Relapsed Hepatoblastoma
Angela Trobaugh-Lotrario
JCCG Registry for Childhood Malignant Solid Tumors
Eiso Hiyama
PSORC
Alex Bondoc
Lessons Learned from the German Liver Tumor Registry
Irene Schmid
Advancing a Prospective Relapsed/Refractory Hepatoblastoma Registry and Collaborative Efforts of the Liver Tumor Research Consortium
James Geller
Count Me In: Empowering Patients and Families to Aid in the Study of a Rare Disease Entity
Alli O’Neill
James Geller, MD
Cincinnati Children’s Hospital
Alli O’Neill, MD
Dana-Farber Cancer Institute
Irene Schmid, MD
Dr. von Hauner Children's Hospital
Angela Trobaugh-Lotrario, MD
Sacred Heart Medical Center – Providence
Alexander Bondoc, MD
Cincinnati Children's Hospital
Eiso Hiyama, MD, PhD
Hiroshima University
4:50-5 pm
Coffee Break
5-6 pm
Alli O’Neill
5- 5:15
Andras Heczey
5:15-5:35 pm
Sanjeev Vasudevan
5:35-5:55 pm
Cutting Edge Advances in Therapies/Novel Therapeutics
ARYA-2: An Engineered TCR for Relapsed/Refractory HB, HCN NOS and HCC
Alli O’Neill
GP3/IL15 CART
Andras Heczey
HDAC Inhibitors for Pediatric Liver Cancer
Sanjeev Vasudevan
Alli O’Neill, MD
Dana-Farber Cancer Institute
Irene Schmid, MD
Dr. Von Hauner Children’s Hospital
Sanjeev Vasudevan
Texas Children’s Hospital
Andras Heczey, MD
Texas Children’s Hospital
5:55-6:10 pm
Marcio Malogolowkin
5:55-6:15 pm
Arun Rangaswami
6:15-6:20 pm
Closing Remarks
Marcio Henrique Malogolowkin, MD
University of California – Davis Health
Arun Rangaswami, MD
UCSF Benioff Children’s Hospitals
6:30-8 pm
Dinner reception
